Mismatch repair and response to DNA-damaging antitumour therapies.
about
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorMismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells.Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cellsDNA replication fidelity and cancerEvolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells.DNA Mismatch Repair.Single molecule studies of DNA mismatch repair.DNA mismatch repair-induced double-strand breaks.Identifying therapeutic targets in gastric cancer: the current status and future directionBiallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics.Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma.Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.The accumulation of DNA repair defects is the molecular origin of carcinogenesis.Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes.Dynamics of MutS-mismatched DNA complexes are predictive of their repair phenotypesSingle-Molecule FRET to Measure Conformational Dynamics of DNA Mismatch Repair Proteins.Generation of DNA-free Escherichia coli cells by 2-aminopurine requires mismatch repair and nonmethylated DNAChromosome fragility at GAA tracts in yeast depends on repeat orientation and requires mismatch repair.Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli.Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.Interaction studies of muts and mutl with DNA containing the major cisplatin lesion and its mismatched counterpart under equilibrium and nonequilibrium conditions.
P2860
Q24306696-F039A183-CA94-4C8D-BD68-6F78F2907532Q24539070-433C792A-CE2D-408C-909B-D939270A1644Q24654966-D5974118-20D0-4916-A843-B718081E5D4DQ28295863-0D1DDF03-BFFF-497E-9D7E-5FA64F585218Q34306599-82BFE18B-5F90-4E21-B0CC-D5BC6BAA7F22Q34509028-3F3545BD-CCA1-4029-BDBD-71E7155DEA9FQ35027619-2744B1D0-69AF-4F2D-AB88-69ABE0F57539Q36328709-D7BDB09A-985B-4A88-9594-9AD114A809C6Q36398732-50E485BF-41A4-4A01-B008-AC1C6EC79501Q37004544-077F46E0-87E1-47F9-A8C5-713F0F64585DQ37069628-A78D3D19-D79A-4D51-922D-2C5B0A8F5574Q37354050-C83CFCCC-DEC4-4471-8687-448BCBDF2018Q37600725-5184A7AE-5639-4E6C-A7AF-3D07FC9DB53BQ38052129-F95799C0-91B2-41A0-8E77-387A35338E06Q38125930-6DD6DBC4-67A5-4000-B814-AC5BB40084EDQ38309335-EE0CCCC1-9F92-43FA-A402-8B594F3C4713Q38739461-610B8CA0-97F5-4A23-A19C-9DFD37F06A3AQ39237485-269281A1-6BF1-4030-B3A0-9C6CD63F934FQ40723784-1A5718B5-22DF-4936-8A41-CD18B958F8C0Q42556770-48D41C6F-3A90-4E8E-9C54-DDA23F6C815EQ42705384-CEBFBF7B-40BA-4369-9540-0E4A333F2706Q43122151-08CA9328-1B6B-4EBD-A7BF-E78FD14F1DC6Q45458727-06C52ECE-5F27-45F0-B056-CD788ABEE1CA
P2860
Mismatch repair and response to DNA-damaging antitumour therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mismatch repair and response to DNA-damaging antitumour therapies.
@ast
Mismatch repair and response to DNA-damaging antitumour therapies.
@en
type
label
Mismatch repair and response to DNA-damaging antitumour therapies.
@ast
Mismatch repair and response to DNA-damaging antitumour therapies.
@en
prefLabel
Mismatch repair and response to DNA-damaging antitumour therapies.
@ast
Mismatch repair and response to DNA-damaging antitumour therapies.
@en
P2093
P1476
Mismatch repair and response to DNA-damaging antitumour therapies.
@en
P2093
P304
P356
10.1016/S0959-8049(03)00569-0
P577
2003-10-01T00:00:00Z